



P.17019/01/2020-PvPI
Indian Pharmacopoeia Commission
National Coordination Centre-Pharmacovigilance Programme of India
(Ministry of Health & Family Welfare, Govt. of India)

Sector-23, Raj Nagar,
Ghaziabad-201002, U.P
Dated: 12th February 2020

Monthly Drugs Safety Alerts

The preliminary analysis of Adverse Drugs Reactions from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

| Sl. No | Suspected Drugs | Indication | Adverse Drugs Reactions |
|---------------|-------------------------|---|--------------------------------|
| 1 | Olanzapine | For the treatment of Schizophrenia. | Hyponatremia |
| 2 | Piperacillin+Tazobactam | In the treatment of LRTI/UTI/Intra abdominal infections, skin and skin structure infections, bacterial septicemic polymicrobial infections. | Blurred Vision |

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above drugs. If such reactions are encountered, please report to the IPC, NCC-PvPI by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “**ADR PvPI App**” and **PvPI Helpline No. 1800-180-3024**.